Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell CarcinomaRobert J. Motzer, Bernard Escudier|New England Journal of Medicine|2018Cited by 4.6k
Tumor mutational load predicts survival after immunotherapy across multiple cancer typesRobert Samstein, Ronald P. DeMatteo, Charles M. Rudin et al.|Nature Genetics|2019Cited by 4.4k
Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in OncologyRobert J. Motzer, Angela D. Motter|Journal of the National Comprehensive Cancer Network|2022Cited by 645
Tivozanib Versus Sorafenib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma: Results From a Phase III TrialRobert J. Motzer, Thomas E. Hutson|Journal of Clinical Oncology|2013Cited by 443
Phase III Randomized Trial of Conventional-Dose Chemotherapy With or Without High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Rescue As First-Line Treatment for Patients With Poor-Prognosis Metastatic Germ Cell TumorsRobert J. Motzer, George J. Bosl|Journal of Clinical Oncology|2007Cited by 351